Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from LLY

What Does the Future Hold for Eli Lilly?

Eli Lilly's two major GLP-1 drugs have dominated headlines, but a slate of new treatments in development—and some already available—suggest a bright future.

MarketBeat

Stock Market Today: Stocks Are Mixed Ahead of CPI

Cool wholesale inflation numbers provide only slight relief before Wednesday's release of December Consumer Price Index data.

Kiplinger

Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity

Eli Lilly shares are down 17.7% from its highs. The company posted 128% YoY revenue jump in its Mounjaro GLP-1/GIP treatment with no signs of slowing down.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly's Q4 2024 Earnings: What to Expect

Eli Lilly is scheduled to release its Q4 earnings report next month, and analysts forecast triple-digit profit growth.

Barchart

Market Correction Got You Down? Try These 2 Bear Call Spread Trades on Thursday

Feeling down about this correction? Don't worry, there's still a way to profit! In this article, we'll show you two bear call spread trades you can make this Friday.

Barchart

Elon Musk Weighs In on Weight-Loss Drug Stocks. Is LLY or NVO a Better Buy?

Elon Musk’s preference for Eli Lilly’s Mounjaro over Novo Nordisk’s Ozempic has sparked increased interest in weight-loss drug stocks.

Barchart

3 Healthcare Stocks to Buy Now for a Healthy Portfolio in 2025

The healthcare industry is set for growth due to the growing demand for quality treatments and ongoing progress in medical technology. Hence, investors might consider investing in healthcare stocks, Eli Lilly (LLY), Thermo Fisher Scientific (TMO), and Abbott Laboratories (ABT) for a healthy portfolio in 2025. Read more….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

MarketBeat Week in Review – 12/2 - 12/6

Equities continued their post-election rally after Friday’s solid November jobs report and all signs point to the rally in stocks extending into 2025

MarketBeat

3 Healthcare ETFs for a Balanced Investment Approach

For investors seeking a balanced approach, healthcare ETFs offer a combination of stability and growth potential. Therefore, it might be wise to consider Fidelity MSCI Health Care Index ETF (FHLC), iShares U.S. Healthcare ETF (IYH), and Vanguard Health Care Index Fund ETF Shares (VHT) for a balanced approach. Keep reading….

StockNews.com

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.

Benzinga

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.

Benzinga

Decoding Eli Lilly's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly (NYSE:LLY).

Benzinga

Is Eli Lilly Stock Outperforming the S&P 500?

Eli Lilly has outperformed the S&P 500 over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

3 Mega-Cap Stocks to Buy Before They're Worth $1 Trillion

These corporate giants could be the next entrants to the $1 trillion market cap club.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Eli Lilly (LLY) vs. Catalent (CTLT): Which Pharma Stock Offers Better Returns?

The pharma industry is evolving rapidly due to the ever-rising healthcare needs and increasing demand for customized medicine and treatments worldwide. So, let’s analyze Eli Lilly (LLY) and Catalent (CTLT), to determine which pharma stock offers better returns. Read more.

Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities.

Benzinga

Behind the Scenes of Eli Lilly's Latest Options Trends

Financial giants have made a conspicuous bearish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:LLY) revealed 8 unusual trades.

MarketBeat

Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch

Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert

STOCK RISES OVER 2.8% AT ITS HIGH FOR THE DAY

Barchart

2 Vaccine Stocks to Buy on the Dip

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

StockNews.com

3 Healthcare ETFs to Buy for Defensive Growth

Healthcare ETFs offer diversified exposure, stable growth, and resilience during downturns, due to steady demand. Therefore, investors may consider strong healthcare ETFs, such as iShares U.S. Healthcare (IYH), Health Care Select Sector (XLV), and Vanguard Health Care Index Fund (VHT) for defensive growth. Read more.

Barchart

Eli Lilly Stock: Is Wall Street Bullish or Bearish?

Eli Lilly has outperformed the broader market and its peers this year, and Wall Street analysts are bullish about the stock’s prospects.

Barchart

Tech Stock Strength Lifts the Broader Market

The S&P 500 Index ($SPX ) (SPY ) today is up +0.17%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.16%. Strength in tech stocks today is lifting the broader market. Alphabet is up more...

Barchart

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

StockNews.com

Is Eli Lilly Still a Top Healthcare Stock After Its Blockbuster Drug Approval?

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes, obesity, and eczema markets, is it a must-have in your healthcare portfolio? Read on to…

1 … 6 7 8 9

People

Gabriel OsorioMazilli

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.